BC PLATFORMS SELECTED TO DELIVER KEY SINGAPORE POPULATION HEALTH STUDY

 

KUALA LUMPUR, Jan 9 (Bernama) -- BC Platforms (BCP), a global leader in healthcare data management and analytics, has been selected to analyse and manage data collected from the Health for Life in Singapore (HELIOS) study, which forms part of the SG100K data set for Singapore's National Precision Medicine programme.

The HELIOS study is a state-of-the-art population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) at Nanyang Technological University, Singapore (NTU Singapore).

According to BCP in a statement, the population study aims to identify environmental, lifestyle and genetic factors that cause heart disease, diabetes, cancer, and other chronic diseases in Singapore.

“I’m delighted that we have more good news coming out of Singapore, a major focus for deploying our clinical solutions and driving precision medicine, where we are working with leading Asian healthcare institutions.

“This latest partnership should make it easier for health service providers to determine optimal patients treatment pathways in major diseases areas, based on population health insights using our genomic data management platform,” said its deputy managing director, Nino da Silva.

As part of Singapore’s SG100K study, the HELIOS study will recruit up to 50,000 men and women, aged 30-84 years old, from the Singapore population progressively over the next two years.

BCP will be providing BC|INSIGHT and BC|RQUEST for management of LKCMedicine’s genotype and phenotype patient data from a large Asian cohort in a safe and secure manner.

The project will benefit from BCP’s latest software solution, the ‘Trusted Collaboration Environment’ and the recently upgraded to its acclaimed BC|INSIGHT open platform version 7.

The platform has a high focus on user experience, it is fully equipped with cohort building tools and capabilities to automate data release approval processes and highly dynamic open workspaces.

-- BERNAMA